Biogen (BIIB) Gains 5% on Strong Q4 Results, Promising Outlook

January 27, 2016 8:23 AM EST

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Biogen (NASDAQ: BIIB) is trading up 4.9% in pre-open trading Wednesday following strong fourth quarter results and solid guidance.

Biogen reported Q4 EPS of $4.50, $0.42 better than the analyst estimate of $4.08. Revenue for the quarter rose 8% to $2.84 billion versus the consensus estimate of $2.71 billion.

TECFIDERA revenues were $993 million compared to $916 million in the same quarter last year. This was above the consensus of $939.5 million.

Biogen sees FY2016 EPS of $18.30-$18.60, versus the consensus of $18.45. Biogen sees FY2016 revenue of $11.1-11.3 billion, versus the consensus of $11.29 billion.

The company is looking to launch three new products this year: BENEPALI®, ZINBRYTATM, and an infliximab biosimilar.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Hot Earnings, Trader Talk

Related Entities

Pre Market Movers